Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus

Highlights • Glycemia and insulin dosage must be frequently monitored and adjusted in people with T2DM and CLD. • By acting faster, lispro analog might reduce the risk of hypoglycemia and provide efficient liver signaling. • A guideline is not available concerning insulin preparations for people wit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes research and clinical practice 2016-03, Vol.113, p.179-186
Hauptverfasser:	Gentile, S, Guarino, G, Strollo, F, Romano, M, Genovese, S, Masarone, M, Ceriello, A
Format:	Artikel
Sprache:	eng
Schlagworte:	Blood Glucose - drug effects Cross-Over Studies Diabetes mellitus Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Endocrinology & Metabolism Female Humans Hyperglycemia - drug therapy Hypoglycemia Hypoglycemic Agents - therapeutic use Insulin - therapeutic use Insulin Lispro - pharmacology Insulin Lispro - therapeutic use Insulin, Regular, Human - pharmacology Insulin, Regular, Human - therapeutic use Lispro insulin Liver cirrhosis Liver Cirrhosis - complications Male Middle Aged Postprandial Period
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Glycemia and insulin dosage must be frequently monitored and adjusted in people with T2DM and CLD. • By acting faster, lispro analog might reduce the risk of hypoglycemia and provide efficient liver signaling. • A guideline is not available concerning insulin preparations for people with CLD and T2DM. • For the first time we show that lispro regulates glucose better than regular insulin in people with CLD and T2DM.
ISSN:	0168-8227 1872-8227
DOI:	10.1016/j.diabres.2015.12.006